Arkolith/Insider Trading/VRDN/Form 4

Myers Scott Dunseth

Chief Executive Officer, DirectorViridian Therapeutics, Inc.\DE (VRDN) · full profile →Form 4 · filed Feb 7, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 6, 2023Grant(A)250K—$0250K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 6, 2023Grant(A)1.0M—$01.0M

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-004238) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML